drugset / Trial / NCT01378091
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
Primary objectives: To determine the maximum tolerated doses (MTDs) of daily lenalidomide and docetaxel given every three weeks and prednisone, as combination therapy to subjects with androgen independent prostate cancer To evaluate the safety profile of the combination of daily lenalidomide and every three week docetaxel and prednisone when given to subjects with androgen independent prostate cancer Secondary objective: To explore the anti-tumor activity of the combination of daily lenalidomide and every 3 week docetaxel and prednisone when given to subjects with androgen independent prostate cancer.
Timeline
- Start
- 2005-08
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Lenalidomide | Other / unclassified | 20 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Lenalidomide | Other / unclassified | 30 mg | — |
| Subject | Lenalidomide | Other / unclassified | 35 mg | — |
| Subject | Lenalidomide | Other / unclassified | 40 mg | — |
| Subject | Prednisone | Other / unclassified | 5 mg | — |